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Abstract
Background: Estimating the risk of developing subsequent primary tumours in a population is
difficult since the occurrence probability is conditioned to the survival probability.
Methods: We proposed to apply Markov models studying the transition intensities from first to
second tumour with the Aalen-Johansen (AJ) estimators, as usually done in competing risk models.
In a simulation study we applied the proposed method in different settings with constant or varying
underlying intensities and applying age standardisation. In addition, we illustrated the method with
data on breast cancer from the Piedmont Cancer Registry.
Results: The simulation study showed that the person-years approach led to a sensibly wider bias
than the AJ estimators. The largest bias was observed assuming constantly increasing incidence
rates. However, this situation is rather uncommon dealing with subsequent tumours incidence. In
9233 cases with breast cancer occurred in women resident in Turin, Italy, between 1985 and 1998
we observed a significant increased risk of 1.91 for subsequent cancer of corpus uteri, estimated
with the age-standardised Aalen-Johansen incidence ratio (AJ-IRstand), and a significant increased risk
of 1.29 for cancer possibly related to the radiotherapy of breast cancer. The peak of occurrence
of those cancers was observed after 8 years of follow-up.
Conclusion: The increased risk of a cancer of the corpus uteri, also observed in other studies, is
usually interpreted as the common shared risk factors such as low parity, early menarche and late
onset of menopause. We also grouped together those cancers possibly associated to a previous
local radiotherapy: the cumulative risk at 14 years is still not significant, however the AJ estimators
showed a significant risk peak between the eighth and the ninth year. Finally, the proposed
approach has been shown to be reliable and informative under several aspects. It allowed for a
correct estimation of the risk, and for investigating the time trend of the subsequent cancer
occurrence.
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Introduction
During the last decades, improvements in medical and
surgical treatments have substantially increased the
chances of surviving from a cancer. Cancer survivors now
amount to more than 3.5% of population in the US [1],
and about 3% in Western Europe [2]. Now more cancer
survivors face the problem of subsequent cancers possibly
related to the late effects of treatments or to a common eti-
ology of first and subsequent cancers. As for other epi-
demics in the past, the challenge is towards a research
effort to address, and possibly prevent, those elements
that increase the chance of developing a second tumour.
And, as in the past, the starting point is to correctly esti-
mate the incidence of multiple primary tumours on a
population basis.
First of all, there is a problem of differential diagnosis,
when it comes to distinguish between local and distant
metastases, recurrences and the onset of a truly new
lesion. Classifications may also vary leading to substantial
differences in rates. For example SEER rules [3] differ sub-
stantially from those adopted by IARC [4]. Timing of mul-
tiple primaries is also important, as they can occur at the
same time (synchronous) or after a time lag (meta-
chronous). Usually synchronous tumours are excluded
from analyses, in the belief that they rather represent prev-
alent silent tumours come to evidence during diagnostic
procedures.
Secondly, it should be taken into account that incidence
rate of multiple primaries is conditional to the probability
of surviving the first tumour, having accumulated suffi-
cient time for developing another one. Usually, the stud-
ied statistics is the ratio between observed and expected
multiple metachronous primary tumours. Expectation is
taken calculating the person-years observed in the cohort
of patients with first tumour, applying general population
incidence rates. In this way, a group of 100 patients with
a short survival of 1 year is equivalent to 10 patients sur-
viving for 10 years. But we know that rarely these two
groups with such a different survival experience can be
compared for several aspects, even without difference in
age distribution. On the contrary, when conditioning on
survival probabilities, we get the same number of
expected cases only when the overall survival is equal to
that of the general population. This assumption holds
true only for those pairs where the first tumour has a
rather benign course with no substantial influence on the
whole survival.
Some of these aspects are not new in the literature, and
they were discussed for deriving expected number of
deaths (or events) for SMR. Keiding offered a historical
perspective of this [5], also showing how one of the oldest
statistical techniques was connected to conditional sur-
vival probabilities and parametric models. The estimation
of the expected number of subsequent cancers adds some
complications to the traditional model and should be
approached in the framework of competing risks, as many
subjects are withdrawn from the population at risk, as
time goes by, by death or censorship. Previous works had
already shown how the traditional Kaplan-Meier estima-
tor is inappropriate in the presence of competing risks [6],
but until now a correct approach taking into considera-
tion competing risks has not yet been applied to the esti-
mation of multiple tumours expected number. In
addition, it is also important to consider the time elapsing
dimension, as subsequent tumours are often more fre-
quent in the first years, and then decrease, with a later rise
after five to eight years depending on the tumour type
[7,8].
These aspects of the problem of estimating probabilities
of subsequent tumours occurrence in the presence of
time-varying rates led us to consider a non-parametric
approach based on multi-state models, which can appro-
priately describe situations where there are several com-
peting outcomes in a time process. Various types of multi-
state models have been proposed for analysing multiple
end-points in different situations; from transplants to
clinical trials and from pregnancy-birth model to infec-
tious disease epidemics (for a review see: [9]). Indeed, we
made use of a stochastic process for estimating the risk of
developing a subsequent cancer, following the enlighten-
ing suggestions offered by Aalen and Gjessing in their
work [10].
Methods
Statistical methods
The tumours occurrence in a general population can be
depicted as in Figure 1. From demographic sources we
know the amount of deaths (me) and the general mortality
rate (μe). From cancer registries we measure the number of
first primary tumours (n1) the incidence rate (λ1), the
number and rates of these patients deceased for other
causes (m1e;μe) and for the specific cause of death (m1;μ1).
After this first process has taken place we can observe (n2)
second primaries with a rate (λ2) to be estimated condi-
tioned to the quantities and parameters previously seen.
Since we were interested in estimating rate of occurrence
after first primary only, we dealt with the simplified
model given in Figure 2. This last one satisfied Markov
assumption, since it did not take into consideration the
past transitions from health state to first tumour. Indeed,
as long as we adopt a simplified model as the one in figure
2, Markov condition is satisfied. Of course, the risk of a
subsequent tumour can depend not only on subject's age,
and his/her current state, but also, for example, on the
therapies adopted for treating the first primary tumour. InPopulation Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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a more sophisticated version of such model these factors
may be introduced as covariates in the transition proba-
bilities.
We applied Markov theory to the process occurring to the
first tumour cohort with two different irreversible and
reciprocally exclusive outcomes: death and second
tumour occurrence. Of course, to calculate transition
intensities in this model it was necessary to also consider
censored observations. We estimated transition intensities
by Nelson-Aalen estimators; then we calculated occur-
rence probabilities conditioned to different events (occur-
rence of a second cancer,   (0, t) death,   (0, t)) in
each time interval with the Aalen-Johansen [11] method
(AJ) in the framework of a Markov process (for details see
Appendix). The proposed model is a simple version of the
competing risk model on which a vast literature already
exists (see, for example, Satten and Datta for marginal esti-
mation of multi-state models with right-censored data
[12]).
In a population of size N, we calculated the cumulative
number of transitions (to second tumour) at the end of
the fourteen years period, as:
We then compared it with the number of expected transi-
tions under the assumption of a Markov model with con-
stant transition intensities equal to those expected from
the general population.
where   (0, 14) is the cancer occurrence probability in
the general population.
So we can derive an incidence ratio for this model:
It must be noted that imposing the same censorship
mechanism in calculating expected cases resulted in a less
biased estimator, since the same bias originated by the
censorship mechanism was at work both in the numerator
and in the AJ-IRdenominator.
We calculated 95 percent confidence limits using the AJ
variance in formula 7 presented in the Appendix.
Age standardisation
Since rates of first and second tumours strongly depend
on age, analysis must be done in age strata or a standard-
isation procedure must be defined. We pursued both strat-
egies grouping age at breast cancer occurrence in five
classes: 0–44, 45–54, 55–64, 65–74, 75+. A standardised
AJ estimator for the whole population can be obtained as
follows:
￿ For each age class k we calculated the  AJ estimator
: let Nk be the number of subjects in class k at
time 0 and set a weight  , where N equals the
sum of the Nk's;
ˆ P12 ˆ P13
trans P N AJ = () ⋅ ˆ ,. 12 01 4
Et r a n s P N AJ g () = () ⋅ ˆ ,; 01 4
ˆ Pg
AJ IR −=
()
transAJ
Et r a n s AJ
.
ˆ , Ps t ijk ()
Wk
Nk
N =
The multi-state model Figure 1
The multi-state model.
The simplified Markov model Figure 2
The simplified Markov model.Population Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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￿ define  ;
￿ under the assumption that weights are deterministic
variables,
￿ so: 
Simulation study
We first carried out a simulation study for validating the
proposed model. Our aim was to compare the estimated
number of second tumours using the AJ estimator with
that obtained with the person-year approach in a simula-
tion. This comparison can be better performed simulating
the process of second tumour occurrence taking under
control biasing factors such as censoring. We then simu-
lated different dynamics of second tumour occurrence.
We considered a simulated cohort of 10000 patients with
a first primary and with same age and period of incidence,
followed up for 10 years. We imposed a survival exponen-
tial law with a constant mortality rate of 0.2. Firstly, occur-
rence of a second primary was kept constant for the whole
follow-up period. We compared the simulated number of
second tumours to the number estimated both by the per-
son-year, and by the AJ approach. We let the second
tumour incidence rate vary from 0.00025 to 0.004, corre-
sponding to a rate ratio of 0.25, 0.5, 1, 2 and 4. Then, the
effect of standardisation by age was investigated repeating
the simulation for the five age classes (each with the same
number of subjects), varying the occurrence rates, but
always keeping them constant for the whole period. Sec-
ondly, the simulation was extended to situations where
also occurrence rates varied in time: at a constant decreas-
ing or increasing trend, or in a bimodal way. Age stand-
ardisation was then applied on bimodal rates simulation.
The simulation engine was based on random chains of
multinomial probabilities M (Pα, Pβ, Pγ) at each time-click
t, with the constraint that Pα + Pβ + Pγ = 1. Pα and Pβ are
normally distributed iper-parameters in a three class
model, respectively representing the probability of transi-
tion from steady state to second tumour and transition
from steady state to death.
Subjects
After the simulation study, we applied the Aalen-Johansen
model to the incidence data from the Piedmont Cancer
Registry (RTP). RTP collects all incident tumours in the
resident population (about one million inhabitants) of
Turin (Italy) since 1985. We selected all first occurrences
of breast cancer (following IARC rules, cases occurring in
the paired breast gland were excluded). We included all
cases diagnosed up to 1998 and then we prolonged the
observation period for detecting subsequent tumours up
to the end of year 2000, allowing for a reasonable amount
of follow-up time also for the last incident cases. We
excluded all cases diagnosed with Death Certificate Only
(DCO), skin cancers other than melanoma and all syn-
chronous tumours.
Results
Simulation study
With a sample size of 10000 subjects replicated for 1000
times we had an average of 55.1 cases with a second
tumour in ten years, given a constant annual death rate of
0.2 and a constant annual second tumour rate of 0.001.
These were estimated as 53.00 cases by the AJ estimator
and as 44.4 cases using the person-year approach (Table
1). Varying the base rate from 0.00025 to 0.004, the per-
centage of bias in the AJ estimators stayed between 3.81%
to 5.80%, while the bias in the number of estimated cases
using the classical amount of person-years ranged
between 19.06% to 19.73%. Age-standardisation aver-
aged the observed bias with 4.75% for the AJ estimator
and 19.42% for the classical approach. In Table 2 we pre-
sented the effect of varying the base incidence rate by fol-
low-up time. We observed a wider bias, that, however,
when averaged by age-standardisation, was kept reasona-
bly low (4.67%) for the AJ estimator and 4.93% for the
person-year approach. The bias was the lowest (+1.25%)
in the case of constantly decreasing rates. Indeed, the
cumulative effects of competing mortality are larger as
time goes by and the bias reached a 14.7% for the AJ esti-
mators, and a 26.3% calculating the estimated cases from
the average person-years, in the case of a constantly
ˆ , ˆ , Ps t W P s t kk k 12 12
stand () =⋅ () ∑
var P s t W var P s t kk
k
ˆ , ˆ ,. 12
2
12
stand () () =⋅ () () ∑
AJ IR
stand
stand
stand −=
()
transAJ
Et r a n s AJ
Table 1: Simulation Study, I
Averages over 1000 simulation runs 0.00025 0.0005 0.001 0.002 0.004 Age-stand.
Number of simulated cases 13.8 27.6 55.1 109.34 218.5 82.5
Number of estimated cases(Aalen-Johansen) 13.0 26.0 53.0 104.0 208.0 78.6
Bias % 5.80 5.80 3.81 4.88 4.81 4.75
Number of estimated cases(person-year) 11.1 22.3 44.4 88.5 175.4 66.5
Bias % 19.25 19.34 19.34 19.06 19.73 19.42Population Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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increasing rate. However, the most frequent case when
dealing with subsequent primary malignancies is the situ-
ation where the rate is constantly decreasing or bimodal.
We must note that the occurrence of a constantly increas-
ing rate is quite uncommon in the real situation.
Risk of a second tumour following breast cancer
We identified 9233 women with breast cancer in Turin
from 1985 to 1998; 249 cases were excluded as they were
identified only from death certificate (DCO), and 58 cases
were excluded since they were synchronous cancers, leav-
ing 8926 cases for analysis. From this cohort, 353 second
(metachronous) primary tumours (excluding skin can-
cers) developed during the prolonged follow-up period
(1985–2000). The completeness of clinical documenta-
tion was rather high, considering that registries work on a
population basis, with a 94.5 percent of microscopic con-
firmation for first tumours that reached 99.3 percent for
second tumours. In Table 3 we presented the observed
number of second tumours by site and the AJ-IRstand that
assumed both observed and expected probabilities fully
conditioned to survival.
A significant risk increase was observed only for corpus
uteri cancer, while the only cancer site with a reduced sta-
tistically significant risk was "other and unspecified". In
addition, AJ-IRstand showed a suggestive risk increase also
for cancers of oesophagus, stomach and pancreas, and for
non-Hodgkin lymphoma, although confidence limits still
included unity. In particular the increased risk of a subse-
quent cancer located in the anatomical sites of oesopha-
gus, stomach, lung or thyroid was suggestive of a late
effect of local radiotherapy of the breast tumor. Grouping
together these cancers, we observed a total of 69 patients,
and the estimated AJ-IRstand was 1.15 (95% C.L.: 1.04–
1.28).
Another interesting feature of the AJ estimator is the pos-
sibility of studying the dynamic of second primary occur-
rence over time. In Figures 3, we presented the time trend
of the  AJ estimator,   (0, t), which is the estimated
cumulative probability of a second primary until time t
for all cancers (Panel A), for cancer of corpus (Panel B),
and for cancers related to breast cancer radiotherapy
ˆ P12
Table 2: Simulation Study, II (1rates = 0.002; 0.0018; 0.00165; 0.0015; 0.00135; 0.0012; 0.001; 0.0008; 0.00065; 0.0005, 2rates = 0.0005; 
0.00065; 0.0008; 0.001; 0.0012; 0.00135; 0.0015; 0.00165; 0.0018; 0.002, 3rates = 0.001; 0.002; 0.001; 0.0005; 0.0005; 0.0005; 0.001; 0.002; 
0.001; 0.0005, 4rates for age groups = annual rates by increasing Relative Risks {0.25; 0.5; 1; 2; 4})
Averages over 1000 simulation runs Constantly decreasing1 Constantly increasing2 Bimodal3 Age-stand.4
Number of simulated cases 83.95 52.81 59.41 88.56
Number of estimated cases(Aalen-Johansen) 85.00 45.00 57.00 84.42
Bias % 1.25 14.79 4.06 4.67
Number of estimated cases(person-year) 66.46 66.72 53.31 84.19
Bias % 20.83 26.34 10.26 4.93
Table 3: Number of observed second tumours in a cohort of women with breast cancer in Turin (Italy), AJ-IR
Cancer Site Observed cases AJ-IRstand (95% C.L.)
Mouth Pharynx 7 0.80 (0.39–1.47)
Oesophagus 5 2.38 (0.92–5.01)
Stomach 29 1.38 (0.97–1.93)
Colon-Rectum 66 0.87 (0.69–1.10)
Liver 7 0.61 (0.23–1.30)
Gallbladder 8 0.78 (0.38–1.40)
Pancreas 20 1.39 (0.89–2.07)
Lung 24 0.80 (0.54–1.15)
Melanoma 14 1.15 (0.65–1.88)
Cervix uteri 9 0.68 (0.34–1.22)
Corpus uteri 54 1.91 (1.47–2.44)
Ovary 24 1.12 (0.74–1.64)
Bladder 14 0.74 (0.42–1.21)
Brain & NS 4 0.56 (0.18–1.31)
Thyroid 11 1.00 (0.46–1.89)
NHL 21 1.32 (0.85–1.94)
Leukaemias 9 0.81 (0.39–1.49)
Other & unspecified 27 0.48 (0.33–0.68)
Total (breast and skin excluded) 353 0.99 (0.91–1.10)Population Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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Cumulative probability of a second tumour after breast cancer. Figure 3
Cumulative probability of a second tumour after breast cancer. Panel A: All cancers (excluding skin cancer). Panel B: 
Corpus Uteri. Panel C: cancers related to radiotherapy (oesophagus, stomach, lung and thyroid gland).   is the cumulative 
observed probability of a second tumour in the cohort of patients with a primary tumour, with its 95% upper (95% ul) and 
lower (95% ll) confidence limits.   is the cumulative estimated probability of a second tumour assuming a constant intensity 
taken from the general population.
ˆ P12
ˆ PgPopulation Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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(Panel C). In particular, Figure 3 showed that there was a
relative increase of probability of developing a second pri-
mary from the fourth to the tenth year after diagnosis of a
breast cancer, even if the cumulative AJ-IR for all cancers
was not significant. For corpus uteri the Figure 3 (Panel B)
showed a persistent increase of risk across all the observa-
tion period. Figure 3 (Panel C) showed an increased risk
after 5 years of follow-up for radiotherapy-related cancers
with a peak at 8 years.
Within this method, it is also possible to provide addi-
tional insights on the variations in occurrence probabili-
ties over time. The mean interval time between two
tumours (calculated over the observed period of 14 years)
was 5.43 for all type of tumours, a little shorter for corpus
uteri (5.27), and notably longer (6.07) for cancers related
to radiotherapy (Table 4). For all cancers and for corpus
uteri the time interval between the two tumours increased
over age, being the shortest (about 2 years) for patients
younger that 45 years of age. In figure 4 we also investi-
gated when probabilities peaks occurred: we found two
peaks at 2 and 8 years. The second peak at 8 years was
mainly sustained by cancers related to radiotherapy and a
AJ-IRstand  value of 1.29 (95% C.L.: 1.25–1.33) was
observed at the eighth year of follow-up.
Discussion
The occurrence of subsequent primary tumours can be
due to several factors. Subsequent malignancies can ini-
tially result from intense clinical surveillance after the first
tumour; they can occur later on as therapies for the first
primary can induce carcinogenesis. Finally, they can also
be due to shared risk factors, including environment, life
styles and inherited genes predisposing to higher suscep-
tibility. However, the high fatality of several cancers hin-
ders the possibility of observing subsequent events, even
if their probability is sensibly increased. Following the
suggestions of Hougaard [9], we applied a simple Markov
model for competing risks and we studied the transition
probabilities from first to second tumour varying in time.
The observed time trend of second primary occurrence is
often not constant with two or more waves of increased
risks during the observed period. For this reason we
resorted to a non-parametric approach, directly calculat-
ing AJ estimators. Some other possible parametric or non-
parametric approaches could be based on a piecewise con-
stant hazard function [13], or on stratification by age or
other covariates when proportional hazard model cannot
be used [14], or multivariate space-state models [15].
However, lack of available clinical information and short-
ness of time series in population-based series of disease
occurrence, as in the case of cancer registry data, hinders
the possibility of fully exploiting the power of more com-
plex models.
Simulation showed how AJ estimators led to less biased
estimates than the person-year method. This is essentially
due to the fact that the AJ estimators are built up taking
into consideration in numerator and in denominator the
exact amount of transitions and person-time at risk at
each time interval. On the contrary, the person-year
method calculates denominators only at the end of the
observation period. Moreover, not only can AJ estimators
give a more precise result at the end of the period, but they
also describe the full probability trend over time. When
keeping the incidence rate constant over the period, the
person-year approach led to a larger bias, underestimating
the number of events. Also the AJ estimator had some lim-
itations; however, the bias was within the 5% error prob-
ability as shown in tables 1 and 2 by the simulation.
The situation is even more complicated with varying rates.
The largest bias was seen with constantly increasing rates.
In this case, the person-year approach gave rise to a larger
than simulated number of events, while the AJ estimator
underestimated the overall number of events, although to
a lesser extent. This limit is due to the unavoidable intro-
duction of discrete time intervals in the analysis of an
intrinsically continuous dimension. In the real situation a
constantly increasing occurrence rate is quite uncommon,
and usually an early increase risk followed by a decrease
or a late peak of incidence is observed. We therefore con-
cluded that we could apply the method of AJ estimators
for analysing subsequent occurrence of cancers after a pri-
mary breast cancer.
Applying the method to the Turin data, we observed an
increased risk of a cancer of the corpus uteri, as also
observed in other studies [16-20], although with lower
Interval probabilities of a second tumour after breast cancer  during the first ten years of follow-up and 95% confidence  bars Figure 4
Interval probabilities of a second tumour after breast 
cancer during the first ten years of follow-up and 95% 
confidence bars.Population Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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values, and it is usually interpreted as the common shared
risk factors such as low parity, early menarche and late
onset of menopause. The most remarkable finding of our
study was an increased risk of oesophagus, stomach, lung
and thyroid cancer.
Indeed, we observed a significant increased risk, grouping
together those cancers possibly associated to a previous
local radiotherapy: the AJ12(s, t) estimators showed a sig-
nificant risk peak between the eighth and the ninth year.
This was suggestive of a late effect of local radiotherapy of
the breast tumour. Other studies [18,20], based on larger
populations and longer follow-up, observed the associa-
tion of breast cancer with oesophagus, stomach, lung and
thyroid cancers. On the other hand, treatment for early-
stage invasive breast cancer shifted in the 1990s from rad-
ical mastectomy substantially without regional radiother-
apy to increasing use of breast-conserving surgery
followed by breast radiation (post-lumpectomy radiation
[21]). In conclusion the proposed approach has been
shown to be valid and informative under several aspects.
It allowed for a reliable estimate of the number of events,
conditioning to observed survival. It also allowed descrip-
tion of the changing pattern of risk over time. Future
developments of the method should be directed to the
parametric modelling of transition probabilities, also in
relation to clinical or epidemiological explanatory varia-
bles.
Appendix
Markov models and Aalen-Johansen estimators
Markov models deal with situations where individuals
can belong to a finite set of states and move to one state
to some others with a probability, possibly depending on
time. The main hypothesis (the Markov assumption) is
that the probability of moving from state i to state j at time
t depends only on i, j and t and not on the previous states.
For every possible move i → j it is defined a transition
intensity map from state i to state j, αij (t), and a cumulative
intensity map   Then we define the
probability transition maps and the probability transition
matrix in the interval [s, t]
The key mathematical ingredient for estimating probabil-
ity transitions maps is the following formula which is
derived from Chapman-Kolmogorov equation for Markov
models:
where u1 < ... <ur is a partition of [s, t] and the limit is taken
for k tending to infinity and the interval lengths tending
to zero; A = {aij} is the upper triangular matrix defined by
In the presence of right censoring, the cumulative inten-
sity maps can be estimated by using the Nelson-Aalen esti-
mators (NA), as follows. For every time t, let Nij (t) be the
number of transitions from state i to state j in the time
interval [0, t], and Yi(t) be the number of individuals
which are in state i at time t. Then the Nelson-Aalen estima-
tor, giving an estimation for the cumulative intensity, is
The estimation of the probability transition matrix can be
obtained by using the values of Nelson-Aalen in formula
(1). We get in this way the Aalen-Johansen (AJ) estimator
for the probability transition matrix:
For a complete reference see the book on statistical mod-
els based on counting processes by Andersen et al [11].
At s d s ij ij
t
() = () ∫ α
0
Ps t i ij(,) = probability for an individual being in state   at   time 
to be in state   at time 
matrix of the 
s
jt
st P ij P(,) = ( (,) ’ st s
PI A A st u u kk
k
, lim () =+ () − () () + ∏ 1 (1)
a
Ai j
ij
ij
ij
=
→
≠
if there is a move 
if   and there is not a mo 0v ve 
if   and   is not an absorbing state
if 
ij
Ai j i
i
ih hi
→
−=
> ∑
0 = =
⎧
⎨
⎪
⎪
⎩
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⎪ ji  and   is an absorbing state
(2)
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Yi
t
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u
ij
t
()
()
()
=∫0
(3)
ˆ , lim ˆˆ . PI A A st u u kk
k
() =+ () − () () + ∏ 1 (4)
Table 4: Mean time (years) occurrence of a subsequent primary cancer in a cohort of women with breast cancer
Subsequent Cancer Site 0–44 Age
45–54
Groups
55–64
65–74 75+ Age-Standardised
All Sites 5.10 5.14 5.36 5.49 6.17 5.43
Corpus uteri 2.03 4.99 4.85 5.52 7.69 5.27
Cancers related to radiotherapy -- 7.33 5.21 5.81 6.96 6.07Population Health Metrics 2009, 7:5 http://www.pophealthmetrics.com/content/7/1/5
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Application to multiple primary tumours
We assumed that the starting time, 0, is the time of diag-
nosis of the first tumour for each individual.
We construct a simple model with three states
1 first tumour
2 second tumour
3 death after a first (but not a second) tumour
where 2 and 3 are absorbing states and the possible moves
are
1 → 2, 1 → 3.
In order to fit our situation in a Markov model, we need
to make sure that every individual goes through at most
one move in every time unity. This is the mathematical
reason for eliminating all sinchronous situations.
According to definitions 3 and 4 we set for every move i →
j:
The estimation of the probability transition matrix can be
obtained by approximating the integral product in for-
mula 4 via time discretisation. We get in this way the AJ
estimator for the probability transition matrix:
where   is the matrix obtained by formula 2 with the
estimated values.
The AJ estimators are consistent and valid also with right
censoring and when the underlying process is non-Mark-
ovian [22].
Following [11] we estimated the variance as:
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